Author

Claudio Bravo

University of Washington - Cited by 545 - Heart Failure

Biography

Dr. Claudio Bravo is from Internal Medicine Department, Bridgeport Hospital/Yale New Haven Health System, Bridgeport, CT, located in USA. His study is about Anomalous Origin of the Left Coronary Artery from Pulmonary Artery (ALCAPA). He is also specialized in Cardiology and Internal Medicine.
Title
Cited by
Year
Type 5 adenylyl cyclase increases oxidative stress by transcriptional regulation of manganese superoxide dismutase via the SIRT1/FoxO3a pathway
L Lai, L Yan, S Gao, CL Hu, H Ge, A Davidow, M Park, C Bravo, ...Circulation 127 (16), 1692-1701, 2013201
98
2013
Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase
K Iwatsubo, C Bravo, M Uechi, E Baljinnyam, T Nakamura, M Umemura, ...American Journal of Physiology-Heart and Circulatory Physiology 302 (12 …, 2012201
51
2012
Meta-analysis and trial sequential analysis comparing percutaneous ventricular assist devices versus intra-aortic balloon pump during high-risk percutaneous coronary …
SA Rios, CA Bravo, M Weinreich, W Olmedo, P Villablanca, MA Villela, ...The American journal of cardiology 122 (8), 1330-1338, 2018201
43
2018
Complete versus culprit‐only revascularisation in ST elevation myocardial infarction with multi‐vessel disease
CA Bravo, SA Hirji, DL Bhatt, R Kataria, DP Faxon, EM Ohman, ...Cochrane Database of Systematic Reviews, 2017201
32
2017
A food and drug administration–approved antiviral agent that inhibits adenylyl cyclase type 5 protects the ischemic heart even when administered after reperfusion
CA Bravo, DE Vatner, R Pachon, J Zhang, SF VatnerJournal of Pharmacology and Experimental Therapeutics 357 (2), 331-336, 2016201
15
2016
Metabolomic analysis of two different models of delayed preconditioning
C Bravo, RK Kudej, C Yuan, S Yoon, H Ge, JY Park, B Tian, WC Stanley, ...Journal of molecular and cellular cardiology 55, 19-26, 2013201
14
2013
A novel adenylyl cyclase type 5 inhibitor that reduces myocardial infarct size even when administered after coronary artery reperfusion
J Zhang, D Levy, M Oydanich, CA Bravo, S Yoon, DE Vatner, SF VatnerJournal of molecular and cellular cardiology 121, 13-15, 2018201
11
2018
Sudden cardiac death as a presentation of anomalous origin of the left coronary artery from pulmonary artery in a young adult
R Pachon, C Bravo, M NiemieraEuropean Heart Journal: Acute Cardiovascular Care 4 (6), 589-590, 2015201
11
2015
Prediction of outcomes after heart transplantation using machine learning techniques
MA Villela, CA Bravo, M Shah, S Patel, UP Jorde, J Stehlik, A CastellanosThe Journal of Heart and Lung Transplantation 3 (4), S25-S26, 2020202
9
2020
Dual-antiplatelet therapy guidelines and implications for perioperative management
K Stawiarski, R Kataria, CA Bravo, P Villablanca, D Mohananey, ...Journal of Cardiothoracic and Vascular Anesthesia 32 (2), 1072-1080, 2018201
9
2018
Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis
W Olmedo, PA Villablanca, C Sanina, J Walker, M Weinreich, J Brevik, ...Vascular 27 (1), 78-89, 2019201
6
2019
The history of durable left ventricular assist devices and comparison of outcomes: HeartWare, HeartMate II, HeartMate 3, and the future of mechanical circulatory support
C Berardi, CA Bravo, S Li, M Khorsandi, JE Keenan, J Auld, S Rockom, ...Journal of Clinical Medicine 11 (7), 2022, 2022202
6
2022
Cochrane corner: complete versus culprit-only revascularisation in ST segment elevation myocardial infarction with multivessel disease
CA Bravo, SA Hirji, DL Bhatt, C Gluud, DP Faxon, EM Ohman, T Kaneko, ...Heart 104 (14), 1144-1147, 2018201
5
2018
Presence of intracardiac thrombus at the time of left ventricular assist device implantation is associated with an increased risk of stroke and death
CA Bravo, JA Fried, JZ Willey, A Javaid, GM Mondellini, L Braghieri, ...Journal of cardiac failure 27 (12), 167-17, 2021202
3
2021
An FDA approved anti-viral agent which inhibits adenylyl cyclase type 5 protects the ischemic heart even when administered after reperfusion
DE Vatner, C Bravo, R Pachon, J Zhang, SF VatnerJournal of Pharmacology and Experimental Therapeutics, 2016201
3
2016
Risk factors for post-transplant outcomes in patients with LVAD support: a machine learning and logistic regression of the UNOS database
CA Bravo, MA Villela, M Shah, R Merekar, PO Mella, A Castellanos, ...The Journal of Heart and Lung Transplantation 39 (4), S410, 000
2
2020
Right heart failure after left ventricular assist device: From mechanisms to treatments
CA Bravo, AG Navarro, KK Dhaliwal, M Khorsandi, JE Keenan, ...Frontiers in Cardiovascular Medicine 9, 103549, 0
2
2022
Disruption of adenylyl cyclase type 5, a novel target for obesity, diabetes and diabetic cardiomyopathy
D Ho, L Yan, X Zhao, C Bravo, W Stanley, DE Vatner, J Pessin, SF VatnerCirculation 26 (suppl_2), A9323-A9323, 20220
1
2012
Recent advance in isoform-specific regulation of adenylyl cyclase
D Wei-Kang Ho, M Umemura, C Bravo, K IwatsuboCurrent Enzyme Inhibition 8 (2), 70-82, 20220
1
2012
Impact of Donor Hemodynamics on Heart Transplant Outcomes: Using Machine Learning Techniques
M Shah, MA Villela, C Bravo, A CastellanosThe Journal of Heart and Lung Transplantation 39 (4), S295, 2020202
1
2020

Referred From: https://scholar.google.com/citations?user=3QKr13gAAAAJ&hl=en&oi=ao

Cited by
Citations 545
h-index 11
i10-index 11
Recommended Journals
Open Access Journals